Efficacy and Safety of the Controlled-release Pregabalin Tablet (GLA5PR GLARS-NF1) and Immediate-release Pregabalin Capsule for Peripheral Neuropathic Pain: A Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Phase III Clinical Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Min-Kyung | - |
dc.contributor.author | Jeon, Younghoon | - |
dc.contributor.author | Choi, Sang Sik | - |
dc.contributor.author | Lee, Pyung Bok | - |
dc.contributor.author | Kim, Yong-Chul | - |
dc.contributor.author | Suh, Jeong Hun | - |
dc.contributor.author | Sim, Sung Eun | - |
dc.contributor.author | Song, Sun Ok | - |
dc.contributor.author | Ko, Youngkwon | - |
dc.contributor.author | Yu, Jae Myung | - |
dc.contributor.author | Min, Kyungwan | - |
dc.contributor.author | Lee, Jae-Hyuk | - |
dc.date.accessioned | 2021-12-08T14:41:58Z | - |
dc.date.available | 2021-12-08T14:41:58Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/130346 | - |
dc.description.abstract | Purpose: This study compared the efficacy and safety of controlled-release pregabalin (GLA5PR GLARS-NF1 tablets) with those of an immediate-release pregabalin capsule after 12 weeks' administration to patients with peripheral neuropathic pain. Methods: In this multicenter, randomized, double-blind, active-controlled, parallel-group, Phase III study, the primary outcome was to confirm that a single treatment with the study drug (after the evening meal) is clinically noninferior to the control drug (BID regimen) at improving the mean Daily Pain Rating Scale score for treating peripheral neuropathic pain. Secondary outcomes were the Daily Sleep Interference Scale, Medical Outcomes Study Sleep Scale, Hospital Anxiety and Depression scale, and frequency of rescue medication use. The safety and tolerability of GLA5PR GLARS-NF1 tablets were also evaluated. The total daily dose of pregabalin is 150-600 mg. Findings: Of the 352 randomized subjects, 261 (n = 130, study group; n = 131, control group) were analyzed. The difference in adjusted mean Daily Pain Rating Scale scores between the groups was -0.11 (95% confidence interval, -0.05 to 0.30), indicating that the study group is noninferior to the control group. There was no statistically significant difference in Daily Sleep Interference Scale, Medical Outcomes Study Sleep Scale, and Hospital Anxiety and Depression scale scores between the groups at treatment termination. Logistic regression analysis revealed no significant difference in the use of rescue medication between the groups (P = 0.217). The overall adverse event profile of the groups was similar, and no serious adverse drug reactions were observed. (C) 2020 Elsevier Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | POSTHERPETIC NEURALGIA | - |
dc.subject | PSYCHOMETRIC PROPERTIES | - |
dc.subject | SLEEP INTERFERENCE | - |
dc.subject | MEDICAL OUTCOMES | - |
dc.subject | ANXIETY | - |
dc.subject | PROFILE | - |
dc.subject | IMPACT | - |
dc.subject | SCALE | - |
dc.title | Efficacy and Safety of the Controlled-release Pregabalin Tablet (GLA5PR GLARS-NF1) and Immediate-release Pregabalin Capsule for Peripheral Neuropathic Pain: A Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Phase III Clinical Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Sang Sik | - |
dc.identifier.doi | 10.1016/j.clinthera.2020.10.009 | - |
dc.identifier.scopusid | 2-s2.0-85096984853 | - |
dc.identifier.wosid | 000600832400006 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.42, no.12, pp.2266 - 2279 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 42 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2266 | - |
dc.citation.endPage | 2279 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | POSTHERPETIC NEURALGIA | - |
dc.subject.keywordPlus | PSYCHOMETRIC PROPERTIES | - |
dc.subject.keywordPlus | SLEEP INTERFERENCE | - |
dc.subject.keywordPlus | MEDICAL OUTCOMES | - |
dc.subject.keywordPlus | ANXIETY | - |
dc.subject.keywordPlus | PROFILE | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | SCALE | - |
dc.subject.keywordAuthor | controlled-release | - |
dc.subject.keywordAuthor | efficacy | - |
dc.subject.keywordAuthor | peripheral neuropathic pain | - |
dc.subject.keywordAuthor | pregabalin | - |
dc.subject.keywordAuthor | safety | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.